Literature DB >> 31315840

A rare case of long-term paraesthesia diagnosed as a paraneoplastic syndrome by anti-SOX1 antibody determination.

Oriol Mirallas1, Nuria Rial1, Berta Martín-Cullell2, Jesus Recio-Iglesias1.   

Abstract

Paraneoplastic syndromes (PS) are a rare presentation of cancer, most commonly associated with small cell lung cancer (SCLC), breast cancer and haematologic malignancies. The diagnosis of PS is challenging because it could affect multiple organ systems and it may present before the tumour is visible by imaging. We report a malignant tumour diagnosed in a male patient who referred long-term paraesthesia and proximal muscle strength loss. After ruling out common causes of polyneuropathy, the anti-SOX1 antibody gave light to the diagnosis. A pulmonary opacity in the upper right lobe was observed in the chest X-ray and a pulmonary tumour was later confirmed by CT scan. The biopsy of the cervical lymphadenopathy determined an SCLC, which caused a PS called Lambert-Eaton myasthenic syndrome (LEMS). Our case raises awareness of a rare PS presentation, which can be diagnosed by specific antibodies, allowing early diagnosis and treatment of lung cancer. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  immunology; lung cancer (oncology); neurooncology; oncology

Mesh:

Substances:

Year:  2019        PMID: 31315840      PMCID: PMC6663210          DOI: 10.1136/bcr-2018-228916

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.

Authors:  P Maddison; J Newsom-Davis; K R Mills; R L Souhami
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

2.  SOX after SOX: SOXession regulates neurogenesis.

Authors:  Michael Wegner
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

Review 3.  Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis.

Authors:  Myrna R Rosenfeld; Josep O Dalmau
Journal:  Continuum (Minneap Minn)       Date:  2012-04

Review 4.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

5.  Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy.

Authors:  M Tschernatsch; P Singh; O Gross; T Gerriets; N Kneifel; C Probst; S Malas; M Kaps; F Blaes
Journal:  J Neuroimmunol       Date:  2010-08-11       Impact factor: 3.478

6.  Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.

Authors:  Paul Maddison; Paul Gozzard; Matthew J Grainge; Bethan Lang
Journal:  Neurology       Date:  2017-03-01       Impact factor: 9.910

Review 7.  Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

Authors:  Maarten J Titulaer; Bethan Lang; Jan Jgm Verschuuren
Journal:  Lancet Neurol       Date:  2011-12       Impact factor: 44.182

8.  Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer.

Authors:  Paul Maddison; Bethan Lang
Journal:  J Neuroimmunol       Date:  2008-07-29       Impact factor: 3.478

9.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

10.  Prevalence of anti-SOX1 reactivity in various neurological disorders.

Authors:  Benjamin Berger; Rick Dersch; Elisabeth Ruthardt; Christiane Rasiah; Sebastian Rauer; Oliver Stich
Journal:  J Neurol Sci       Date:  2016-09-04       Impact factor: 3.181

View more
  1 in total

1.  Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer: A case report.

Authors:  Sizhu Gong; Yue Han; Enling He; Min Liu; Xiyao Fu; Fang Deng
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.